 |
 |

COMMENTS AND OPINIONS
Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides—Reply
Sophie M. Worobec, MD
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In reply
We respectfully disagree with Di Lernia's comment that patients with pilar MF, F-MF, or folliculotropic cutaneous T-cell lymphoma (CTCL) "should always be considered to have tumor-stage disease."
We are familiar with the 2002 article by van Doorn et al1 that describes 51 patients with F-MF who had disease-specific survival rates of 68% at 5 years and 26% at 10 years and posits that the prognosis for F-MF is similar to that for epidermotropic tumor-stage disease.1 However, Di Lernia did not cite 2 more recent reports that give much better survival rates for F-MF. In a 2005 report,2 the European Organization for Research on the Treatment of Cancer classifies F-MF as a distinct subgroup. The 5-year survival rate of 86 patients with F-MF is reported to be 80%, while that of 800 patients with classic MF is 88%.2 A 2008 report by Gerami et al3 . . . [Full Text of this Article] AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Progression of Undiagnosed Cutaneous T-Cell Lymphoma During Efalizumab Therapy
Claudia Hernandez, Sophie M. Worobec, Sujata S. Gaitonde, Monika L. Kiripolsky, and Kristen Aquino
Arch Dermatol. 2009;145(1):92-94.
EXTRACT
| FULL TEXT
RELATED LETTER
Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides
Vito Di Lernia
Arch Dermatol. 2009;145(7):843-844.
EXTRACT
| FULL TEXT
|